Our top pick for
Epizyme, Inc is a biotechnology business based in the US. Epizyme shares (EPZM) are listed on the NASDAQ and all prices are listed in US Dollars. Epizyme employs 203 staff and has a trailing 12-month revenue of around USD$13.8 million.
Since the stock market crash in March caused by coronavirus, Epizyme's share price has had significant negative movement.
Its last market close was USD$11.85, which is 52.37% down on its pre-crash value of USD$24.88 and 18.99% down on the lowest point reached during the March crash when the shares fell as low as USD$14.1.
If you had bought USD$1,000 worth of Epizyme shares at the start of February 2020, those shares would have been worth USD$721.82 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$553.99.
|Latest market close||USD$11.85|
|52-week range||USD$10.51 - USD$27.82|
|50-day moving average||USD$12.5129|
|200-day moving average||USD$15.1536|
|Wall St. target price||USD$28.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.862|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||2.95%|
|1 month (2020-10-23)||-11.04%|
|3 months (2020-08-24)||-7.49%|
|6 months (2020-05-22)||-36.22%|
|1 year (2019-11-22)||-27.83%|
|2 years (2018-11-23)||59.49%|
|3 years (2017-11-24)||-0.42%|
|5 years (2015-11-24)||-23.20%|
|Revenue TTM||USD$13.8 million|
|Gross profit TTM||USD$-108,839,000|
|Return on assets TTM||-31.98%|
|Return on equity TTM||-65.22%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 10.4 million Epizyme shares held short by investors – that's known as Epizyme's "short interest". This figure is 12% up from 9.3 million last month.
There are a few different ways that this level of interest in shorting Epizyme shares can be evaluated.
Epizyme's "short interest ratio" (SIR) is the quantity of Epizyme shares currently shorted divided by the average quantity of Epizyme shares traded daily (recently around 937374.8870822). Epizyme's SIR currently stands at 11.07. In other words for every 100,000 Epizyme shares traded daily on the market, roughly 11070 shares are currently held short.
However Epizyme's short interest can also be evaluated against the total number of Epizyme shares, or, against the total number of tradable Epizyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Epizyme's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Epizyme shares in existence, roughly 100 shares are currently held short) or 0.1382% of the tradable shares (for every 100,000 tradable Epizyme shares, roughly 138 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Epizyme.
Find out more about how you can short Epizyme stock.
We're not expecting Epizyme to pay a dividend over the next 12 months.
Over the last 12 months, Epizyme's shares have ranged in value from as little as $10.51 up to $27.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Epizyme's is 1.8014. This would suggest that Epizyme's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.